Product Name :
U-101017
Description:
U-101017 is a partial agonist of benzodiazepine receptor and GABAA receptor, with anxiolytic effects.
CAS:
170568-47-5
Molecular Weight:
442.94
Formula:
C23H27ClN4O3
Chemical Name:
tert-butyl 7-chloro-5-[(3R,5S)-3,5-dimethylpiperazine-1-carbonyl]imidazo[1,5-a]quinoline-3-carboxylate
Smiles :
CC(C)(C)OC(=O)C1N=CN2C=1C=C(C1C=C(Cl)C=CC2=1)C(=O)N1C[C@H](C)N[C@H](C)C1
InChiKey:
JOJRKTAQXYPHBT-OKILXGFUSA-N
InChi :
InChI=1S/C23H27ClN4O3/c1-13-10-27(11-14(2)26-13)21(29)17-9-19-20(22(30)31-23(3,4)5)25-12-28(19)18-7-6-15(24)8-16(17)18/h6-9,12-14,26H,10-11H2,1-5H3/t13-,14+
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.Bivalirudin manufacturer
Additional information:
U-101017 is a partial agonist of benzodiazepine receptor and GABAA receptor, with anxiolytic effects.Cariprazine custom synthesis |Product information|CAS Number: 170568-47-5|Molecular Weight: 442.94|Formula: C23H27ClN4O3|Chemical Name: tert-butyl 7-chloro-5-[(3R,5S)-3,5-dimethylpiperazine-1-carbonyl]imidazo[1,5-a]quinoline-3-carboxylate|Smiles: CC(C)(C)OC(=O)C1N=CN2C=1C=C(C1C=C(Cl)C=CC2=1)C(=O)N1C[C@H](C)N[C@H](C)C1|InChiKey: JOJRKTAQXYPHBT-OKILXGFUSA-N|InChi: InChI=1S/C23H27ClN4O3/c1-13-10-27(11-14(2)26-13)21(29)17-9-19-20(22(30)31-23(3,4)5)25-12-28(19)18-7-6-15(24)8-16(17)18/h6-9,12-14,26H,10-11H2,1-5H3/t13-,14+|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.PMID:32223569 |Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|PNU-101017 potentiates GABA-stimulated Cl- currents at low concentrations (In Vivo:|Pre-ischemic treatment with either PNU-101017 significantly protects the CA1 neuronal population, and PNU-101017 reduces the loss to 50%. Delaying PNU-101017 administration until immediately after reperfusion does not reduce the neuroprotective activity. U-101017 (30 μmol/kg, p.o.) time-dependently blocks [3H]FNZ binding to the mouse cerebral cortex. U-101017 dose-dependently decreases the levels of cGMP with ED50s of 260.0 (163-425) and 0.37 (0.12-1.04) in nonstressed and foot shock-stressed mice, respectively. Flumazenil, an antagonist of GABAA receptors, has no significant effect on cGMP in nonstressed mice, but pretreatment with flumazenil significantly blocks U-101017 (10 μmol/kg, p.o.)-induced reductions in cGMP. In stressed mice, flumazenil is ineffective in altering cerebellar cGMP, but pretreatment with these doses of flumazenil significantly (p Products are for research use only. Not for human use.|